Citigroup’s Intersect ENT, Inc XENT Stock Holding History

Citigroup’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$92K	–	7758
2020 Q4	$92K	Sell	4,000 -300	-7%	-$5.71K	﹤0.01%	5606
2020 Q3	$70K	Sell	4,300 -32,900	-88%	-$596K	﹤0.01%	5366
2020 Q2	$504K	Buy	37,200 +23,900	+180%	+$278K	﹤0.01%	4262
2020 Q1	$158K	Buy	13,300 +13,100	+6,550%	+$290K	﹤0.01%	4935
2019 Q4	$5K	Sell	200 -23,700	-99%	-$480K	﹤0.01%	7419
2019 Q3	$407K	Buy	23,900 +22,500	+1,607%	+$410K	﹤0.01%	4539
2019 Q2	$32K	Buy	+1,400	New	+$37.8K	﹤0.01%	6826
2018 Q4	–	Sell	-94,200	Closed	-$2.71M	–	7891
2018 Q3	$2.71M	Buy	+94,200	New	+$2.83M	﹤0.01%	2452

Citigroup's XENT Position: Q2 2022 in Review

Citigroup sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 2,231 shares — an estimated $63K sold.

Citigroup first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.47M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Citigroup reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Citigroup sold 2,231 Intersect ENT, Inc shares in Q2 2022, an estimated $63K.
Citigroup first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
Citigroup's Intersect ENT, Inc position peaked at $9.47M in Q3 2021.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.